[Treatment of malignant brain tumors by the intrathecal administration of BAR (EUdR-antimetabolite-radiation)].
D000230:Adenocarcinoma / Q000628:therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D000963:Antimetabolites / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000628:therapy*; D001973:Bromodeoxyuridine / Q000008:administration & dosage* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D004806:Ependymoma / Q000628:therapy; D005260:Female; D005909:Glioblastoma / Q000628:therapy; D006801:Humans; D007278:Injections, Spinal; D008297:Male; D008527:Medulloblastoma / Q000628:therapy; D008579:Meningioma / Q000628:therapy; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D008937:Mitomycins / Q000627:therapeutic use; D010871:Pinealoma / Q000628:therapy; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D011882:Radiotherapy, High-Energy; D012175:Retinoblastoma / Q000628:therapy
D000963:Antimetabolites; D008937:Mitomycins; D011838:Radiation-Sensitizing Agents; D001973:Bromodeoxyuridine; D008727:Methotrexate